Proactive Investor's  Instablog

Proactive Investor
Send Message
Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
My company:
My blog:
  • Soligenix Profiled In Article As It Readies For Two Key Drug Trials 0 comments
    Jul 16, 2013 3:08 PM | about stocks: SNGX

    Soligenix (OTCBB:SNGX), a company that is developing several promising drug candidates, was featured Tuesday in an article on, which profiled the drug developer that is preparing to begin phase 2 clinical testing of its two lead products later this year.

    After closing a $7.1 million financing last month, the company is planning to start phase 2 clinical trials for SGX942, which is designed to treat oral mucositis in head and neck cancer patients, and which recently received investigational new drug clearance from the U.S. FDA.

    It second lead candidate, SGX203, is being developed as a potential treatment for pediatric Crohn's disease.

    But these two candidates are just one part of the company's potential, with a huge pipeline that in biotherapeutics and vaccines for biodefense that BioTuesdays writer Leonard Zehr highlights are targeting indications that each has a market potential of at least $200 million plus.

    The company earlier this month teamed up with SciClone Pharmaceuticals (NASDAQ:SCLN) and gained access to SciClone's oral mucositis clinical and regulatory data library in exchange for commercialization rights for SGX942 in China, including Hong Kong and Macau.

    It also as recently as May signed a collaboration deal with Intrexon, which is controlled by billionaire biotech entreprenuer Randal (RJ) Kirk, to develop and commericalize human monoclonal antibody therapies for new biodefense and infectious disease applications for melioidosis, a deadly disease for which there is no prevantative vaccine or immunotherapy.

    The article cited Dr. Christopher Schaber as saying that the deal is unique "because the goal is to develop a therapy that will treat both a deadly disease currently affecting millions of people as well as fight a potential biological weapon". Melioidosis is listed as a top five high-priority threat in the HHS2012 public health emergency medical countermeasures enterprise strategic plan.

    Aside from its biotherapeutics business, the company is also focused on biodefense countermeasures, with the product generating the most buzz being RiVax, a vaccine to protect against ricin poisoning, expected to begin phase 2 trials in 2014. RiVax has received U.S. federal funding and, if approved, would likely be purchased under government contract. Soligenix's biodefense program also includes OrbeShield for GI acute radiation syndrome (NYSE:ARS), involving its two-tablet immediate- and delayed-released formulation of oral BDP (beclomethasone 17, 21-dipropionate), which is "awaiting a decision on a contract proposal which was made to BARDA last February", wrote Zehr.

    The company's stock has so far risen 85 per cent this year, and is currently sitting at around $1.11.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: SNGX
Back To Proactive Investor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.